Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHighmark Pennsylvania Wegovy Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentHighmark PennsylvaniaPolicy N/A

    Medication prior authorization form for Wegovy (coverage criteria)

    Customize your policy alerts

    Sign up for all Highmark Pennsylvania policy alerts

    Know when Highmark Pennsylvania releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    A payer-specific prior authorization form used by providers to request coverage for Wegovy (semaglutide) and collect required member, provider, medication, and clinical information to support medical necessity determinations. Applies to providers submitting authorization requests to Highmark in the covered service regions.

    Policy Summary
    PayerHighmark Pennsylvania
    PolicyMedication prior authorization form for Wegovy (coverage criteria)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit a separate completed prior authorization form (one per medication) with member, provider, medication, and clinical information; fax to 1-866-240-8123 or mail to the address provided.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Wegovydrug targeted by form

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    31
    number of clinical questions
    1-866-240-8123fax submissions

    Coverage Criteria for Wegovy (semaglutide)

    Clinical information requested

    Information requested to support medical necessity for Wegovy

    Lifestyle program participation: Member is using Wegovy in combination with a lifestyle modification program that encourages reduced calorie diet and increased physical activity; provider must specify duration (months) of active participation and attach supporting documentation (examples: provider chart notes, recurring program receipts, dietary logs, recurring nutrition counseling appointments).

    Attach one form of documentation for diet and one for physical activity as listed on the form.

    Prior weight-loss therapies: Provide prior weight-loss medications tried and failed with dates (examples: Contrave, Saxenda, Qsymia, Xenical, Zepbound, prior Wegovy) and attach documentation.

    List dates of therapy for each prior medication trial.

    Baseline measures: Provide baseline (prior to any weight-loss medication) height, weight, and BMI with supporting documentation (for example, chart notes).
    Concurrent GLP-1 use: Document whether Wegovy is being used with another GLP-1 receptor agonist or GLP-1 combinations (for example, with insulin); indicate current use on the form.
    Zepbound intolerance: If asserted, document therapeutic intolerance or contraindication to Zepbound (severe side effects not resolved by diet modification or dose de‑escalation, or documented allergic reaction/hypersensitivity) with supporting documentation.
    Cardiovascular use and comorbidity: Document whether Wegovy is being used for major adverse cardiovascular event risk reduction, presence of pre-existing cardiovascular disease (prior stroke or myocardial infarction), peripheral arterial disease (and supporting ABI, revascularization, or amputation documentation), diabetes or prediabetes status, and current standard pharmacologic therapy for comorbid conditions.

    Attach chart notes when applicable.

    MASH/NASH-specific requirements: If Wegovy is used for Metabolic‑Dysfunction Associated Steatohepatitis (MASH/NASH): indicate prescribing specialty (gastroenterologist/hepatologist), provide confirmatory testing (biopsy, NITs, ELF) with dates, provide fibrosis staging (F0–F4), document risk factors (BMI, waist circumference, fasting glucose, 2‑hour glucose, HbA1c, triglycerides, HDL, blood pressure), confirm absence of cirrhosis/hepatic decompensation/HCC, document alcohol intake within limits, and provide evidence of continued use of standard‑of‑care pharmacologic treatments for comorbid diseases.

    If MASH/NASH is selected, complete and attach documentation for questions 22–31 on the form.

    Statin intolerance assessment: If statin intolerance is reported, document specific severe events (for example, hospitalization for rhabdomyolysis, CK/LFT elevations) and trials of at least two different statins that resolved on discontinuation.

    Select hospitalization or other severe event as applicable and attach supporting documentation.

    Continuation

    Continuation therapy / current use queries

    Current Wegovy therapy: Indicate if the member is currently on Wegovy and whether continued therapy is required; if on therapy for MASH/NASH, provide evidence of improvement or stabilization of fibrosis by noninvasive tests (NITs) and confirm ongoing use of standard‑of‑care pharmacologic treatments for comorbid conditions.

    If member is currently on Wegovy, complete questions 29–31 and attach documentation demonstrating improvement/stabilization where applicable.

    The prior authorization form specifically asks whether Wegovy is being used for major adverse cardiovascular event (MACE) risk reduction and whether it is being prescribed for Metabolic-Dysfunction Associated Steatohepatitis (MASH/NASH). For MACE, the form captures prior cardiovascular history (for example, prior stroke or myocardial infarction) and requests attached documentation when present. For MASH/NASH, the form requires confirmation that testing was performed (biopsy, noninvasive tests, ELF blood test, etc.), dates of testing, and fibrosis staging (F0–F4), and it requests documentation of relevant risk factors (BMI, waist circumference, fasting and 2‑hour glucose, HbA1c, lipids, blood pressure) and ongoing standard-of-care management. The form also queries whether Wegovy is being used concurrently with another GLP‑1 receptor agonist or with insulin, and asks providers to document prior GLP‑1 therapy failure/intolerance when applicable.

    Completion and submission of the prior authorization form does not itself guarantee payment. The form instructions state that providers must submit a separate completed form for each medication and fax or mail the form with supporting clinical documentation, and they note that payment is subject to member eligibility and that authorization does not guarantee payment.

    Clinical Thresholds and Coding-Adjacent Criteria

    Prediabetes and related lab thresholds
    Hemoglobin A1c (A1c)5.7%–6.4%
    Fasting plasma glucose (FPG)100–125 mg/dL
    Oral glucose tolerance test (OGTT)140–199 mg/dL
    Alcohol consumption limits
    Female alcohol consumption limit≤20 g/day
    Male alcohol consumption limit≤30 g/day
    DocumentationForm asks provider to attest alcohol use is within these limits for MASH/NASH consideration

    Submission and Documentation Requirements

    Prior Authorization

    One prior authorization form per medication; submit with clinical documentation

    Submit a separate completed prior authorization form for each medication; include member, provider, medication, and clinical information. Fax the completed form and all clinical documentation to 1-866-240-8123 or mail to 120 Fifth Avenue, SPECARE, Pittsburgh, PA 15222.

    Step Therapy

    Document prior weight‑loss medication trials and dates

    List prior weight-loss medications the member has tried and failed and provide dates of therapy (examples listed on the form include Contrave, Saxenda, Qsymia, Xenical, Zepbound, and previous Wegovy). Attach documentation to support these prior treatment attempts.

    • Provide dates of therapy for each prior medication listed on the form

    Background and Purpose

    This form collects the clinical details necessary to support medical necessity for initiating or continuing Wegovy (semaglutide). Required information includes documentation of participation in a lifestyle modification program (reduced calorie diet and increased physical activity) with duration and supporting evidence, baseline anthropometrics (height, weight, BMI), and a record of prior weight‑loss medications tried and dates. The form also requests condition‑specific evaluations where applicable (for example, MASH/NASH testing and fibrosis staging) and asks for documentation of therapeutic intolerance or contraindication to alternatives such as Zepbound when asserted.

    Definitions and Program Examples

    Lifestyle modification program
    Examples of programsNutritional counseling or comprehensive weight management programs (e.g., Noom, Weight Watchers, Vida, Lark, Signos, Wondr, Omada)
    Required elementsPrograms must encourage reduced calorie diet and increased physical activity
    Acceptable documentationProvider chart notes, recurring receipts/subscriptions, dietary logs, or recurring nutrition counseling appointment records

    Initial Therapy Requirements

    Initial therapy

    Information required for initiating Wegovy

    Required initiation data: Provide documentation of participation in a lifestyle modification program that includes both reduced calorie diet and increased physical activity with duration in months and supporting documents (diet and physical activity evidence), baseline height/weight/BMI prior to any weight‑loss medication, and a list of prior weight‑loss medication trials with dates and supporting documentation.

    Acceptable documentation examples are specified on the form (chart notes, program receipts, dietary logs, wearable device reports, etc.).

    Continuation Therapy Requirements

    Continuation therapy

    Questions for members currently on Wegovy

    Continuation documentation: If the member is currently on Wegovy and requests continued therapy, indicate need for continued therapy and, when used for MASH/NASH, provide evidence of improvement or stabilization of fibrosis by NITs; confirm continued use of standard‑of‑care pharmacologic treatments for comorbid diseases and attach relevant documentation.

    Complete questions 29–31 on the form when member is on therapy and attach supporting clinical data.

    Prior Medication Trial Requirements

    Previous weight-loss medicationDates of therapy
    Contrave(provider to list dates of therapy)
    Saxenda(provider to list dates of therapy)
    Qsymia(provider to list dates of therapy)
    Xenical(provider to list dates of therapy)
    Zepbound(provider to list dates of therapy; include documentation of intolerance if asserted)
    Previous Wegovy therapy(provider to list dates of prior Wegovy therapy)
    Other (specify)(provider to list medication name and dates of therapy)

    Quantity and Supply

    Wegovy — quantity and day supply
    Requested quantityProvider must specify the requested quantity on the form
    Requested day supply options28 days, 84 days, or other specified day supply (provider to mark or enter)
    DirectionsForm includes a directions field for dosing and titration plans

    Site of Care and Administrative Notes

    Note

    No site-of-care restriction on the form

    The form is an administrative submission and does not restrict site of care; providers may submit regardless of intended site of administration.

    Policy Summary
    PayerHighmark Pennsylvania
    PolicyMedication prior authorization form for Wegovy (coverage criteria)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective Date
    Next Review Date
    Key ActionSubmit a separate completed prior authorization form (one per medication) with member, provider, medication, and clinical information; fax to 1-866-240-8123 or mail to the address provided.
    SourceLink
    On This Page
    Coverage Criteria for Wegovy (semaglutide)Clinical Thresholds and Coding-Adjacent CriteriaSubmission and Documentation RequirementsBackground and PurposeDefinitions and Program ExamplesInitial Therapy RequirementsContinuation Therapy RequirementsPrior Medication Trial RequirementsQuantity and SupplySite of Care and Administrative Notes
    BMI or waist criteria for MASH risk factors
    Body mass index (BMI)≥25 kg/m2
    Waist circumference — males≥94 cm
    Waist circumference — females≥80 cm
    Documentation Required

    Attach required supporting documentation (diet, activity, clinical data)

    Attach documentation supporting lifestyle program participation and relevant clinical data; acceptable documentation includes chart notes, recurring receipts or logs, wearable device reports, prior medication trial records, baseline height/weight/BMI, and test/lab results (for example, MASH/NASH confirmation and fibrosis staging) as indicated on the form.

    • Diet documentation: chart notes, recurring program receipts, or dietary logs
    • Physical activity documentation: chart notes, gym receipts, wearable device summaries, or trainer receipts
    • Clinical data: prior medication trials, baseline height/weight/BMI, biopsy or NITs/ELF for MASH with dates, fibrosis staging, and relevant labs
    Denial Risk

    Authorization does not guarantee payment; verify member eligibility

    Payment is subject to member eligibility; an authorization decision does not guarantee payment for the requested services.